PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity

Includes Detailed Profiles of Industry Giants; AstraZeneca, GlaxoSmithKline (GSK), Pfizer, Inc., Merck & Co., Inc., Clovis Oncology, Novartis International AG, Roche Holding AG, and Bristol-Myers Squibb. Global PARP Inhibitor Biomarkers Market Global PARP Inhibitor Biomarkers Market Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "PARP Inhibitor Biomarkers Market by Product, Service, Application, End User, and Region" report has been added to ResearchAndMarkets.com's offering. This comprehensive research ...